BriaPro Therapeutics Corp. released its unaudited Condensed Interim Consolidated Financial Statements for the three-month period ending October 31, 2025, showcasing the company's financial performance and position.
The financial statements demonstrate the current assets, liabilities, and shareholders' equity of BriaPro Therapeutics Corp.
Management confirms the preparation of these financial statements in accordance with International Financial Reporting Standards.
Preparation Standard
The financial statements were prepared following International Financial Reporting Standards by the company's management.
Auditor Review
The independent auditor did not review the financial statements, as disclosed in the filing, abiding by the relevant regulations.
Shareholders' Deficit
Detailed breakdown of the shareholders' deficit, including share capital, share-based payment reserve, and accumulated deficit.
- The financial statements reveal a comprehensive overview of BriaPro Therapeutics Corp.'s financial health for the specified period.
- Investors can gain insights into the company's cash flow, assets, liabilities, and operating performance from the disclosed information.
BriaPro Therapeutics Corp.'s Q4 2025 financial statements provide transparency into the company's financial standing, serving as a valuable resource for shareholders and potential investors to assess the firm's performance.